Abstract
We herein report the synthesis of 3β-substituted amides of 17a-aza-D-homo-4-androsten-17-one (11a-11r) from commercially available Diosgenin as the starting material. The structures of newly synthesized compounds were confirmed by IR, 1H NMR, 13C NMR and mass spectrometry. All the synthesized analogues were tested for their 5α- reductase inhibitory and antimicrobial activity, some of them exhibit moderate to potent activity comparable to the reference drugs. Among the synthesized derivatives the analogue (11r) 3β-(indonlylbutanamido)-17a-aza-D-homo-4- androsten-17-one was found to be active against both 5-reductase enzyme and microbial strains, whereas the analogue (11i) 3β-(3,4-dimethoxy-benzamido)-17a-aza-D-homo-4-androsten-17-one was found to be the least active. The detailed 5-reductase inhibitors and antimicrobial activities of the synthesized compounds were reported.
Keywords: 5α-Reductase, Antibacterial, Antifungal, Dutasteride, Ciprofloxacin, Voriconazole.
Current Topics in Medicinal Chemistry
Title:Synthesis and Characterization of 3β-Substituted Amides of 17a-Aza-Dhomo- 4-androsten-17-one as Potent 5α-Reductase Inhibitors and Antimicrobial Agents
Volume: 13 Issue: 16
Author(s): Manav Malhotra, Rajiv Sharma, Ravindra K. Rawal, Hemraj Heer and T. R. Bhardwaj
Affiliation:
Keywords: 5α-Reductase, Antibacterial, Antifungal, Dutasteride, Ciprofloxacin, Voriconazole.
Abstract: We herein report the synthesis of 3β-substituted amides of 17a-aza-D-homo-4-androsten-17-one (11a-11r) from commercially available Diosgenin as the starting material. The structures of newly synthesized compounds were confirmed by IR, 1H NMR, 13C NMR and mass spectrometry. All the synthesized analogues were tested for their 5α- reductase inhibitory and antimicrobial activity, some of them exhibit moderate to potent activity comparable to the reference drugs. Among the synthesized derivatives the analogue (11r) 3β-(indonlylbutanamido)-17a-aza-D-homo-4- androsten-17-one was found to be active against both 5-reductase enzyme and microbial strains, whereas the analogue (11i) 3β-(3,4-dimethoxy-benzamido)-17a-aza-D-homo-4-androsten-17-one was found to be the least active. The detailed 5-reductase inhibitors and antimicrobial activities of the synthesized compounds were reported.
Export Options
About this article
Cite this article as:
Malhotra Manav, Sharma Rajiv, Rawal K. Ravindra, Heer Hemraj and Bhardwaj R. T., Synthesis and Characterization of 3β-Substituted Amides of 17a-Aza-Dhomo- 4-androsten-17-one as Potent 5α-Reductase Inhibitors and Antimicrobial Agents, Current Topics in Medicinal Chemistry 2013; 13 (16) . https://dx.doi.org/10.2174/15680266113139990131
DOI https://dx.doi.org/10.2174/15680266113139990131 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Timely Review of State-of-the-Art Chronopharmaceuticals Synchronized with Biological Rhythms
Current Drug Delivery Galectins: Major Signaling Modulators Inside and Outside the Cell
Current Molecular Medicine New Perspectives in Glioma Immunotherapy
Current Pharmaceutical Design lGnRH-III - a Promising Candidate for Anticancer Drug Development
Protein & Peptide Letters Clomiphene Citrate, Metformin or Both for Ovulation Induction in Therapy Naïve Women with Polycystic Ovary Syndrome (PCOS)? A Descriptive Review
Current Drug Therapy Promising Anticancer Drug Candidates Based on the 7-methoxychromone Scaffold: Synthesis and Evaluation of Antiproliferative Activity
Letters in Drug Design & Discovery Pharmaceutical Perspectives of HECT-TYPE Ubiquitin Ligase Smurf1
Current Pharmaceutical Design Prostate Cancer Prevention in the Developing World - What are we Waiting for?
Current Pharmacogenomics and Personalized Medicine Nano-pharmaceutical Formulations for Targeted Drug Delivery against HER2 in Breast Cancer
Current Cancer Drug Targets Social Determinants, Race, and Brain Health Outcomes: Findings from the Chicago Health and Aging Project
Current Alzheimer Research Human Kallikreins: Common Structural Features, Sequence Analysis and Evolution
Current Genomics Subject Index To Volume 6
Endocrine, Metabolic & Immune Disorders - Drug Targets Effects of Physical Exercise on Inflammatory Markers of Atherosclerosis
Current Pharmaceutical Design Depression in Older Persons with Mobility Limitations
Current Pharmaceutical Design Dual Roles of Sulforaphane in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Angiogenesis and Vascularization of Uterine Leiomyoma: Clinical Value of Pseudocapsule Containing Peptides and Neurotransmitters
Current Protein & Peptide Science Chemoprevention of Cancer by Isothiocyanates and Anthocyanins: Mechanisms of Action and Structure-Activity Relationship
Current Medicinal Chemistry Repressing the Activity of Protein Kinase CK2 Releases Mitochondria-Mediated Apoptosis in Cancer Cells
Current Drug Targets Antioxidant Clinical Trials in Mild Cognitive Impairment and Alzheimer’s disease – Challenges and Perspectives
Current Pharmaceutical Design Clinical Significance of Breast Cancer Resistance Protein/ABCG2 in the Management of Malignancy
Clinical Cancer Drugs